It has been proposed that serum ProGRP can detect drug resistance early and evaluate its effectiveness in monitoring treatment with tyrosine kinase inhibitors in patients with advanced, inoperable MTC.17 Here, GRP is linked to medullary thyroid gland carcinoma.